Literature DB >> 11320077

Functionally different agonists induce distinct conformations in the G protein coupling domain of the beta 2 adrenergic receptor.

P Ghanouni1, Z Gryczynski, J J Steenhuis, T W Lee, D L Farrens, J R Lakowicz, B K Kobilka.   

Abstract

G protein-coupled receptors represent the largest class of drug discovery targets. Drugs that activate G protein-coupled receptors are classified as either agonists or partial agonists. To study the mechanism whereby these different classes of activating ligands modulate receptor function, we directly monitored ligand-induced conformational changes in the G protein-coupling domain of the beta(2) adrenergic receptor. Fluorescence lifetime analysis of a reporter fluorophore covalently attached to this domain revealed that, in the absence of ligands, this domain oscillates around a single detectable conformation. Binding to an antagonist does not change this conformation but does reduce the flexibility of the domain. However, when the beta(2) adrenergic receptor is bound to a full agonist, the G protein coupling domain exists in two distinct conformations. Moreover, the conformations induced by a full agonist can be distinguished from those induced by partial agonists. These results provide new insight into the structural consequence of antagonist binding and the basis of agonism and partial agonism.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11320077     DOI: 10.1074/jbc.C100162200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  120 in total

Review 1.  G protein-coupled receptor drug discovery: implications from the crystal structure of rhodopsin.

Authors:  J Ballesteros; K Palczewski
Journal:  Curr Opin Drug Discov Devel       Date:  2001-09

2.  Receptor conformations involved in dopamine D(2L) receptor functional selectivity induced by selected transmembrane-5 serine mutations.

Authors:  J Corey Fowler; Supriyo Bhattacharya; Jonathan D Urban; Nagarajan Vaidehi; Richard B Mailman
Journal:  Mol Pharmacol       Date:  2012-03-13       Impact factor: 4.436

Review 3.  Functional selectivity in GPCR heterocomplexes.

Authors:  J González-Maeso; S C Sealfon
Journal:  Mini Rev Med Chem       Date:  2012-08       Impact factor: 3.862

Review 4.  Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.

Authors:  Terry Kenakin; Laurence J Miller
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

Review 5.  Ensemble of G protein-coupled receptor active states.

Authors:  P S-H Park
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

Review 6.  Β-arrestin: a signaling molecule and potential therapeutic target for heart failure.

Authors:  Nabila Noor; Chetan B Patel; Howard A Rockman
Journal:  J Mol Cell Cardiol       Date:  2010-11-11       Impact factor: 5.000

7.  Agonist binding to the NMDA receptor drives movement of its cytoplasmic domain without ion flow.

Authors:  Kim Dore; Jonathan Aow; Roberto Malinow
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-09       Impact factor: 11.205

Review 8.  Structural insights into G-protein-coupled receptor activation.

Authors:  William I Weis; Brian K Kobilka
Journal:  Curr Opin Struct Biol       Date:  2008-11-17       Impact factor: 6.809

9.  Identifying conformational changes of the beta(2) adrenoceptor that enable accurate prediction of ligand/receptor interactions and screening for GPCR modulators.

Authors:  Kimberly A Reynolds; Vsevolod Katritch; Ruben Abagyan
Journal:  J Comput Aided Mol Des       Date:  2009-01-16       Impact factor: 3.686

10.  Co-evolving stability and conformational homogeneity of the human adenosine A2a receptor.

Authors:  Francesca Magnani; Yoko Shibata; Maria J Serrano-Vega; Christopher G Tate
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-29       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.